These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 33613932)

  • 1. The role of acalabrutinib in adults with chronic lymphocytic leukemia.
    Fakhri B; Andreadis C
    Ther Adv Hematol; 2021; 12():2040620721990553. PubMed ID: 33613932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An update on acalabrutinib to treat chronic lymphocytic leukemia.
    Blackmon A; O'Brien S
    Drugs Today (Barc); 2021 Jul; 57(7):417-431. PubMed ID: 34268530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acalabrutinib and Its Therapeutic Potential in the Treatment of Chronic Lymphocytic Leukemia: A Short Review on Emerging Data.
    Isaac K; Mato AR
    Cancer Manag Res; 2020; 12():2079-2085. PubMed ID: 32256115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia.
    Ghia P; Dlugosz-Danecka M; Scarfò L; Jurczak W
    Leuk Lymphoma; 2021 May; 62(5):1066-1076. PubMed ID: 33427570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acalabrutinib: a bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia.
    Wolska-Washer A; Robak T
    Expert Rev Hematol; 2022 Mar; 15(3):183-194. PubMed ID: 35296194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The evolving role of Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia.
    Gordon MJ; Danilov AV
    Ther Adv Hematol; 2021; 12():2040620721989588. PubMed ID: 33796237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the pharmacokinetics of acalabrutinib in the treatment of chronic lymphocytic leukemia.
    Miao Y; Xu W; Li J
    Expert Opin Drug Metab Toxicol; 2021 Sep; 17(9):1023-1030. PubMed ID: 34275396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell Malignancies.
    Abbas HA; Wierda WG
    Front Oncol; 2021; 11():668162. PubMed ID: 34055635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. US Food and Drug Administration approvals for Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukemia: Potential inefficiencies in trial design and evidence generation.
    Kim MS; Prasad V
    Cancer; 2020 Oct; 126(19):4270-4272. PubMed ID: 32644193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BTK Inhibitors in Chronic Lymphocytic Leukemia.
    Gaballa S; Pinilla-Ibarz J
    Curr Hematol Malig Rep; 2021 Oct; 16(5):422-432. PubMed ID: 34599723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted Treatment of Chronic Lymphocytic Leukemia: Clinical Utility of Acalabrutinib.
    Vitale C; Gibbons JL; Ferrajoli A
    Onco Targets Ther; 2021; 14():5507-5519. PubMed ID: 35002256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of BTK Inhibitors in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Practical Guidance.
    St-Pierre F; Ma S
    Blood Lymphat Cancer; 2022; 12():81-98. PubMed ID: 35911566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Covalent Bruton's Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia.
    Alsouqi A; Woyach JA
    Clin Lymphoma Myeloma Leuk; 2024 May; ():. PubMed ID: 38897870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acalabrutinib and its use in treatment of chronic lymphocytic leukemia.
    Khan Y; O'Brien S
    Future Oncol; 2019 Feb; 15(6):579-589. PubMed ID: 30381956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zanubrutinib in lymphoproliferative disorders: a comprehensive review.
    Muñoz J; Wang Y; Jain P; Wang M
    Ther Adv Hematol; 2022; 13():20406207221093980. PubMed ID: 35651781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acalabrutinib and its use in the treatment of chronic lymphocytic leukemia.
    Egyed M; Lueff S; Borbely J; Illes A
    Future Oncol; 2022 Mar; 18(7):755-769. PubMed ID: 35139644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies.
    Danilov AV; Persky DO
    Br J Haematol; 2021 Apr; 193(1):15-25. PubMed ID: 33216986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three-year cardiovascular and non-cardiovascular adverse events in patients with chronic lymphocytic leukemia or small cell lymphocytic lymphoma treated with Bruton tyrosine kinase inhibitors acalabrutinib or ibrutinib: a real-world analysis.
    Nunes RAB; Avezum Á; de Oliveira Marques M; Baiocchi OCCG; Bachour P
    Ann Hematol; 2024 Nov; 103(11):4613-4620. PubMed ID: 39153144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Evolution of Therapies Targeting Bruton Tyrosine Kinase for the Treatment of Chronic Lymphocytic Leukaemia: Future Perspectives.
    Eyre TA; Riches JC
    Cancers (Basel); 2023 May; 15(9):. PubMed ID: 37174062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia.
    Woyach JA; Blachly JS; Rogers KA; Bhat SA; Jianfar M; Lozanski G; Weiss DM; Andersen BL; Gulrajani M; Frigault MM; Hamdy A; Izumi R; Munugalavadla V; Quah C; Wang MH; Byrd JC
    Cancer Discov; 2020 Mar; 10(3):394-405. PubMed ID: 31915195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.